Effective July 1, 2020 the CMS HCPCS Workgroup created a new HCPCS code, C1849 for “Skin substitute, synthetic, resorbable, per square centimeter”. CMS has designated C1849 as a high-cost skin substitute under the Medicare Outpatient Prospective Payment System.
Clinical outcomes, presented in 3 posters, made a profound impression on clinicians managing patients' acute and chronic wounds.
Nanofiber Solutions, with Phoenix Wound Matrix, was pleased to participate in the 2019 MHSRS Scientific Meeting. The MHSRS is the Department of Defense’s premier scientific meeting. It provides a venue for presenting new scientific knowledge resulting from military-unique research and development.
Jed Johnson will be representing RenovoDerm at the 2017 Heal Ohio Wound Care Conference on Thursday, November 2nd. Heal Ohio is a statewide collaborative that aims to unite scientists, healthcare professionals, and commercial partners who share a common vision and mission to solve problems associated with wound care. In doing this, it will serve to bridge the gaps that exist between clinics, research, business, and patients.
The 2017 Heal Ohio Conference will be devoted to health professional presentations and feature informative learning sessions and keynote addresses. Activities are expected to provide an atmosphere rich in collaboration and networking for both career and research advancement.
Today, RenovoDerm announced that the U.S. Food and Drug Administration (FDA) has cleared its proprietary product, the Phoenix Wound Matrix.
The Phoenix Wound Matrix is a fully resorbable electrospun device designed to mimic the extracellular matrix (ECM) found naturally in the body. This product will be used for the treatment of acute, chronic, and burn wounds, which continues to be a concern for both doctors and patients.
